Marco Antonio Marra is a Distinguished Scientist and Director of Canada's Michael Smith Genome Sciences Centre at the BC Cancer Research Centre and Professor of Medical Genetics at the University of British Columbia (UBC). He also serves as UBC Canada Research Chair in Genome Science for the Canadian Institutes of Health Research and is an inductee in the Canadian Medical Hall of Fame.
The Kolling Institute is located in the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.
The Victor Chang Cardiac Research Institute (VCCRI) is an Australian non-profit medical research facility that is dedicated to finding cures for cardiovascular disease. With headquarters located in Darlinghurst, New South Wales, the research hub is home to more than 20 research laboratories and the Victor Chang Cardiac Research Institute Innovation Centre. The institute's mission is "the relief of pain and suffering, and the promotion of well-being, through an understanding of the fundamental mechanisms of cardiovascular disease". Its key research is focused on the prevention and treatment of various heart diseases, including arrhythmia, cardiac arrest, cardiomyopathy, congenital heart disease, heart attack, heart failure, high cholesterol, obesity, spontaneous coronary artery dissection (SCAD) and stroke.
Christopher Carl Goodnow is an immunology researcher and the current executive director of the Garvan Institute of Medical Research. He holds the Bill and Patricia Ritchie Foundation Chair and is a Conjoint Professor in the faculty of medicine at UNSW Sydney. He holds dual Australian and US citizenship.
David Ernest James is a cell biologist who discovered the glucose transporter GLUT4. He has also been responsible for the molecular dissection of the intracellular trafficking pathways that regulate GLUT4 translocation to the cell surface, the topological mapping of the insulin signal transduction pathway, the creation of a method for studying in vivo metabolism in small animals, and the use of this method to gain insights into whole-animal fuel metabolism and homeostasis.
Elaine R. Mardis is the co-executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital, where she also serves as the Nationwide Foundation Endowed Chair in Genomic Medicine. She also is professor of pediatrics at the Ohio State University College of Medicine. Mardis’s research focuses on the genomic characterization of cancer and its implications for cancer medicine. She was part of the team that reported the first next-generation-based sequencing of a whole cancer genome, and participated extensively in The Cancer Genome Atlas (TCGA) and the Pediatric Cancer Genome Project (PCGP).
John Stanley Mattick is an Australian molecular biologist known for his efforts to assign function to non-coding DNA. Mattick was the executive director of the Garvan Institute of Medical Research from 2012 to 2018. He joined Genomics England in May 2018 as chief executive officer. In October 2019, he joined the University of New South Wales in Sydney.
Genomics England is a company set up and owned by the United Kingdom Department of Health and Social Care to run the 100,000 Genomes Project. The project aimed in 2014 to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. An infectious disease strand is being led by Public Health England.
The 100,000 Genomes Project is a now-completed UK Government project managed by Genomics England that is sequencing whole genomes from National Health Service patients. The project is focusing on rare diseases, some common types of cancer, and infectious diseases. Participants give consent for their genome data to be linked to information about their medical condition and health records. The medical and genomic data is shared with researchers to improve knowledge of the causes, treatment, and care of diseases. The project has received over £300 million from public and private investment.
Vanessa Hayes is a geneticist conducting research into cancer genomics and comparative human genomics. She leads a research group at the Garvan Institute of Medical Research in Sydney Australia and holds the Petre Chair of Prostate Cancer Research at the University of Sydney.
Alan Stuart Coates is an Australian professor of clinical oncology, medical researcher and administrator. He was the inaugural CEO of the Cancer Council Australia (1998–2006), former president of the Clinical Oncological Society of Australia (COSA), and co-chair of the St. Gallen International Breast Cancer Conference. He was also the first non-American to be elected to the board of directors of the American Society of Clinical Oncology.
Leslie "Les" Lazarus was an Australian endocrinologist who was one of the first two Directors of the Garvan Institute of Medical Research, Sydney from 1966 to 1969 and sole Director from 1969 to 1990. At the Garvan Institute he led a joint laboratory and clinical research team studying diabetes and pituitary hormone secretions, in particular the secretion and clinical uses of human growth hormone.
Clinicogenomics, also referred to as clinical genomics, is the study of clinical outcomes with genomic data. Genomic factors have a causal effect on clinical data. Clinicogenomics uses the entire genome of a patient in order to diagnose diseases or adjust medications exclusively for that patient. Whole genome testing can detect more mutations and structural anomalies than targeted gene testing. Furthermore, targeted gene testing can only test for the diseases for which the doctor screens, whereas testing the whole genome screens for all diseases with known markers at once.
Núria López Bigas is a Spanish biologist and research professor with expertise in medical genetics, computational biology, and bioinformatics. She is an ICREA professor at Pompeu Fabra University and she also leads the Biomedical Genomics Research Group at the Institute for Research in Biomedicine in Barcelona, Spain. Her research is focused on developing computational approaches to investigate cancer genomes.
Andrew Victor Biankin is a Scotland-based Australian clinician-scientist, best known for his work on enabling precision oncology in learning healthcare systems by integrating discovery, preclinical and clinical development to accelerate novel therapeutic strategies, and developing standardised pan-cancer assays for use by healthcare systems and researchers worldwide.
Lesley Veronica Campbell is an Australian endocrinologist and Professor of Medicine with a special interest in clinical diabetes, appetite and metabolism. She is a principal research fellow at the Garvan Institute of Medical Research in Sydney, Australia.
Susan J. Clark is an Australian biomedical researcher in epigenetics of development and cancer. She was elected a Fellow of the Australian Academy of Science in 2015, and is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and Research Director and Head of Genomics and Epigenetics Division at the Garvan Institute of Medical Research. Clark developed the first method for bisulphite sequencing for DNA methylation analysis and used it to establish that the methylation machinery of mammalian cells is capable of both maintenance and de novo methylation at CpNpG sites and showed is inheritable. Clark's research has advanced understanding of the role of DNA methylation, non-coding RNA and microRNA in embryogenesis, reprogramming, stem cell development and cancer, and has led to the identification of epigenomic biomarkers in cancer. Clark is a founding member of the International Human Epigenome Consortium (IHEC) and President of the Australian Epigenetics Alliance (AEpiA).
Katherine Samaras is the laboratory head at the Garvan Institute of Medical Research. She holds positions at St Vincent's Clinic, and University of New South Wales, as well as the University of Notre Dame.
The University of Glasgow's Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer.
